Moon Hee Lee

ORCID: 0000-0002-5965-1815
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Treatment and Pharmacology
  • Colorectal Cancer Treatments and Studies
  • Cancer survivorship and care
  • Advanced Breast Cancer Therapies
  • Lymphoma Diagnosis and Treatment
  • Breast Cancer Treatment Studies
  • Gastric Cancer Management and Outcomes
  • Childhood Cancer Survivors' Quality of Life
  • Multiple Myeloma Research and Treatments
  • Blood disorders and treatments
  • Viral-associated cancers and disorders
  • Neutropenia and Cancer Infections
  • Acute Myeloid Leukemia Research
  • Metastasis and carcinoma case studies
  • Histiocytic Disorders and Treatments
  • HER2/EGFR in Cancer Research
  • Lung Cancer Treatments and Mutations
  • Diabetes Management and Education
  • Birth, Development, and Health
  • Fungal Infections and Studies
  • Chronic Myeloid Leukemia Treatments
  • Hematopoietic Stem Cell Transplantation
  • Cancer-related Molecular Pathways
  • Acute Kidney Injury Research
  • Pneumocystis jirovecii pneumonia detection and treatment

Inha University
2016-2025

Inha University Hospital
2010-2024

Lee University
2018

National University College
2013

New Generation University College
2013

Asan Medical Center
2013

University of Ulsan
2013

Soonchunhyang University
2013

Seoul National University
2013

Yonsei University
2013

Abstract Purpose This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically 17p deletion and TP53 mutations. Methods We conducted a systematic literature review identify all publicly available randomized controlled trials (RCTs) using PubMed, EMBASE, Cochrane database, meeting abstracts published through December 2023. A Bayesian was...

10.1007/s44313-024-00038-2 article EN Blood Research 2025-01-02

The primary purpose of our study was to evaluate whether maintenance chemotherapy with paclitaxel/gemcitabine (PG) superior observation in improving progression-free survival (PFS) patients metastatic breast cancer (MBC) who achieved disease control an initial six cycles PG as their first-line treatment.The a prospective, randomized, multicenter, phase III trial. Patients MBC after were randomly assigned or until progression.Of 324 from 10 centers enrolled, 231 exhibited (complete response +...

10.1200/jco.2012.45.2490 article EN Journal of Clinical Oncology 2013-04-09

Prevalence and Relationships of Iron Deficiency Anemia with Blood Cadmium Vitamin D Levels in Korean WomenAnemia, iron deficiency (ID), anemia (IDA) are common disorders.This study was undertaken to determine the prevalence anemia, ID, IDA females.We examined associations between IDA, heavy metals blood, vitamin level nutritional intakes.The performed using on data collected from 10,169 women (aged ≥ 10 yr), including 1,232 2,030 690 during fifth Korea National Health Nutrition Examination...

10.3346/jkms.2016.31.1.25 article EN cc-by-nc Journal of Korean Medical Science 2016-01-01

The Advanced Lung Cancer Inflammation Index (ALI, body mass index × albumin/neutrophil-to-lymphocyte ratio) has been demonstrated to be a prognostic factor of survival in some solid cancers. We retrospectively investigated the usefulness ALI predict chemotherapy response and 212 patients with diffuse large B cell lymphoma (DLBCL) treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Patients were allocated low group (n = 82, 38.7%) or high 130,...

10.1159/000452991 article EN Acta Haematologica 2017-01-01

This study aimed to analyze the differences of soluble endoglin (sEng) and transforming growth factor-beta1 (TGF-beta1) according preeclamptic complications investigate correlation between these factors clinical symptoms preeclampsia.We estimated levels sEng TGF-beta1 in plasma collected second trimester at time genetic amniocentesis from 60 women who subsequently developed preeclampsia 124 contemporaneous normotensive women.sEng were higher cases than controls, whereas lower (P < 0.001)....

10.1002/pd.2217 article EN Prenatal Diagnosis 2009-02-27

We aimed to describe the prevalence and correlates of unmet needs among non-Hodgkin lymphoma (NHL) survivors in Korea identify their association with health-related quality life (HRQOL).Participants were 826 NHL from three hospitals South diagnosed at least 24 months prior participating (mean, 6.3 years; range, 2.1-20.9 years). used self-reported questionnaires, including Need Scale for Cancer Patients Undergoing Follow-up Care (NS-C) developed EORTC QLQ-C30. defined an need as a moderate...

10.1002/pon.4136 article EN Psycho-Oncology 2016-04-13

In the era of CDK4/6 inhibitors in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, few trials have been specifically studied to compare quality life between palbociclib plus endocrine therapy (ET) and cytotoxic chemotherapy exclusively premenopausal women. We aimed evaluate differences patient report outcomes (PROs) ET capecitabine. PROs were assessed using EORTC QLQ-C30 at baseline, every 6 weeks, end treatment. All QLQ-30 scores maintained from baseline Patients...

10.3390/cancers12113265 article EN Cancers 2020-11-05

Cetuximab is a monoclonal antibody targeting epidermal growth factor receptor (EGFR). The present study investigated the association between germline genetic polymorphisms and treatment outcome of cetuximab plus modified leucovovin, fluorouracil, oxaliplatin (FOLFOX)6 chemotherapy in advanced gastric cancer (AGC). DNA from peripheral blood mononuclear cells 38 patients enrolled phase II FOLFOX6 were analyzed for 16 eight genes (EGFR, factor, transforming factor-alpha (TGFA), thymidylate...

10.1111/j.1349-7006.2009.01447.x article EN other-oa Cancer Science 2009-11-23

Pegylated granulocyte-colony-stimulating factor (G-CSF) is frequently used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy with a high risk of myelosuppression. This phase II/III study was conducted determine the adequate dose pegteograstim, new formulation pegylated G-CSF, and evaluate efficacy safety pegteograstim compared pegfilgrastim.In II part, 60 breast cancer who were DA (docetaxel doxorubicin) or TAC (docetaxel, doxorubicin, cyclophosphamide) randomly...

10.1007/s00520-015-2963-7 article EN cc-by-nc Supportive Care in Cancer 2015-09-30

Objective: BK virus-hemorrhagic cystitis (BKV-HC) is a potential cause of morbidity and mortality in patients having undergone allogeneic stem cell transplantation (Allo-SCT).We analyzed the clinical features BKV-HC following Allo-SCT reported utility leflunomide therapy for BKV-HC.Materials Methods: From January 2005 to June 2014, among 69 that underwent our institution, who experienced were investigated retrospectively.Results: HC was observed 30 (43.5%), them, 18 cases (26.1%) identified...

10.4274/tjh.2015.0131 article EN Turkish Journal of Hematology 2016-01-21

Plasmablastic lymphoma (PBL) of the oral cavity is an acquired immunodeficiency syndrome-related lymphoma. The immunophenotype this disease associated with poor expression B-cell markers but a positive reactivity for plasma cell markers. PBL highly aggressive and responds poorly to treatment. Although originally described in cavity, can occur other body niches. Here, we describe very rare case anal canal 40-year-old woman human virus infection. malignant cells were Epstein-Barr herpes 8.

10.4143/crt.2009.41.3.182 article EN Cancer Research and Treatment 2009-01-01

Purpose We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with cisplatin (SP) as adjuvant chemotherapy for stage gastric cancer patients. Materials and Methods Stage patients who had received curative gastrectomy D2 lymphadenectomy were randomized into equal groups receive of eight cycles DS (S-1 70 mg/m2/day on days 1-14 35 mg/m2on 1 8) every 3 weeks or SP 60 day 1) weeks. The primary endpoint was 3-year disease-free survival (DFS) rate. Results...

10.4143/crt.2018.028 article EN Cancer Research and Treatment 2018-02-05

Background Self-efficacy has become the target outcome of many self-management interventions for cancer survivors. However, no measurement is available that can be used to measure cancer-specific self-efficacy in Korea. Objective The aim this study was cross-culturally evaluate reliability and validity a Korean version Cancer Survivors' Self-Efficacy Scale (CSSES-K). Methods We translated original CSSES (11 items) created version. then conducted validation with 204 survivors who had...

10.1097/ncc.0000000000000691 article EN Cancer Nursing 2018-12-29

1007 Background: Endocrine treatment is preferred recommendation by clinical guidelines in premenopausal as well postmenopausal women with hormone receptor(HR)-positive, HER2-negative metastatic breast cancer(MBC). In real-world practice, however, substantial numbers of patients are treated chemotherapy earlier lines based on endocrine resistance and/or physician’s concern worse prognosis associated aggressive tumor behavior and younger age. terms the regimens, capecitabine seems one most...

10.1200/jco.2019.37.15_suppl.1007 article EN Journal of Clinical Oncology 2019-05-20

Due to rarity of factor V (FV) deficiency, there have been only a few case reports in Korea.We retrospectively analysed the clinical-laboratory features FV deficiency 10 Korean patients.Between January 1987 and December 2013, published journal or proceedings Korea Society on Thrombosis Hemostasis were reviewed.Severity is defined as mild (> 5% activity), moderate (1%-5%), severe (< 1%).The median age at diagnosis, six males four females, was 26 years (range, 1 month-73 years).Six patients...

10.3346/jkms.2016.31.2.208 article EN cc-by-nc Journal of Korean Medical Science 2016-01-01

To examine the effectiveness of partnErship-based, needs-tailored self-Management support Program fOr Women with breast cancER (EMPOWER), a partnership-based, needs-tailored, self-management (SM) intervention designed to empower post-treatment cancer survivors (BCSs) and ultimately improve their health outcomes.

10.1002/pon.5828 article EN Psycho-Oncology 2021-09-22
Coming Soon ...